Beijing Double-Crane Pharmaceutical To Set Up Large-Scale Production Base In Wuhan
This article was originally published in PharmAsia News
Beijing Double-Crane Pharmaceutical recently revealed that it will set up a large-scale pharmaceutical base with an investment of RMB 270 million in Wuhan city, Hubei province. The facility is to adopt world-standard cutting-edge technology, and upon completion will help elevate Beijing Double-Crane to the number one position in the local industry. The initial planning has been done and construction will be commencing soon. The Wuhan government is placing great importance on the project and has been providing support to the firm. (Click here for more - Chinese Language)
You may also be interested in...
Created last year under the Office of New Drugs reorganization, ONDP works to promote regulatory consistency while fostering innovation – and reacting to unexpected challenges like the pandemic.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.